34 results about "Mrna expression" patented technology

The application relates to the technical field of biological medicine and fundus disease treatment, in particular to application of Acbd3 in treatment of fundus diseases. It is found that the mRNA expression level and the protein expression level of Acbd3 in the retina of a fundus disease model mouse are significantly higher than those of a control group. After an Acbd3 inhibitor is used, the inflammatory reaction and neuron apoptosis in the retina of the fundus disease model mouse are significantly relieved, abnormal activation of Muller cells and microglia cells can be reduced, and a damaged blood-retina barrier can be repaired.

The application provides a group of small interfering RNAs (siRNAs) targeting pyroptosis-related inflammatory reaction genes and application thereof. The pyroptosis-related inflammatory reaction genes include IL1A, IL1B, IL6, HMGB1, S100A8, S100A9 and BACH1. The application designs and synthesizes specific siRNA sequences for the above genes, and verifies that the siRNAs can efficiently and specifically inhibit the mRNA expression level of the corresponding genes through cell transfection and real-time fluorescent quantitative PCR. The application also provides a composition containing the siRNAs, a pharmaceutical composition and application thereof in the preparation of a drug for treating diseases mediated by pyroptosis-related inflammatory reaction genes (especially inflammatory diseases). The siRNAs and the composition thereof provide a new effective strategy for treating diseases related to excessive activation of pyroptosis-related inflammatory reactions, and have a wide application prospect.

This invention discloses a heterozygous sesquiterpene tricyclic epoxy compound derived from the strain *Arthrum oligosporum*, its preparation method, and its applications, belonging to the field of natural product chemistry. This invention provides a heterozygous sesquiterpene tricyclic epoxy compound derived from *Arthrum oligosporum* (… A.oligospora ) AOL_ s00210g57 Anthrobotrisin D, a novel heterozygous sesquiterpene tricyclic epoxy compound from a gene knockout strain, has been shown in vitro to possess excellent anti-inflammatory activity, significantly inhibiting lipopolysaccharide-induced inflammatory responses in mouse microglia. It exhibits a clear dose-dependent inhibitory trend at multiple levels, including NO release, protein and mRNA expression of inflammatory factors (TNF-α, IL-1β, IL-6), and iNOS protein and mRNA expression. Furthermore, at a concentration of 33 μM, its anti-inflammatory effect is comparable to that of the clinically proven positive drug dexamethasone, and in some aspects, it is even superior. This invention not only provides a new lead compound for the development of anti-inflammatory drugs but also opens up new directions for developing new drugs from the unique microbial resource of nematode-preying fungi.

The application relates to the field of biotechnology, in particular to application of CADM1 in preparation of a drug for gestational diabetes mellitus. The application comprises: using a detection reagent for detecting the expression level of CADM1 in preparation of a detection drug for gestational diabetes mellitus. The application is based on the previous research of the applicant that the expression level of CADM1 in the placental trophoblast of a gestational diabetes mellitus patient is reduced, and it is found in an in-vitro experiment that CADM1 can promote the proliferation, migration and invasion of the placental trophoblast cells, and by constructing an mRNA expression amount of CADM1 and a receiver operating characteristic curve of a subject of a GDM patient, it is indicated that the mRNA expression amount of CADM1 is related to the GDM patient, which indicates that CADM1 is related to the placental trophoblast of the gestational diabetes mellitus patient, and it is indicated that the detection of the gestational diabetes mellitus can be realized by detecting the detection reagent for detecting the expression level of CADM1.

This invention relates to genetic engineering technology and aims to provide a method for preparing and applying bacteriophage capsid protein MS2-armored PRRSV antigen mRNA particles. The method includes: inserting the MS2 bacteriophage capsid protein gene and an mRNA expression cassette into a double multiple cloning site expression vector; transforming the recombinant expression plasmid into host bacteria; inducing expression to allow the MS2 capsid protein to express and self-assemble into virus-like particles; utilizing the specific recognition of the MS2 capsid protein on the packaging stem-loop structure, packaging the transcribed mRNA inside the virus-like particles to form MS2-armored PRRSV antigen mRNA particles; lysing the host bacteria, separating the supernatant, and enriching and purifying the particles. This invention significantly enhances the resistance of mRNA to nuclease degradation and improves formulation stability; it can increase the efficiency of mRNA entering antigen-presenting cells and enhance immunogenicity; it can be mass-produced with controllable processes and relatively low cost.

The application discloses a postbiotic prepared from paracasei CCFM1294 and having the function of improving the HA content of skin cells, and belongs to the technical field of microorganisms. The postbiotic prepared from paracasei CCFM1294 has the function of promoting the synthesis of HA of a host: (1) significantly up-regulating the UGDH mRNA expression of skin cells; (2) significantly up-regulating the HAS1 mRNA expression of skin cells; (3) significantly up-regulating the HAS2 mRNA expression of skin cells; (4) significantly up-regulating the HAS3 mRNA expression of skin cells; (5) increasing the HA content of skin cells; therefore, the postbiotic prepared from paracasei CCFM1294 has the function of promoting the synthesis of HA of a host and preventing and / or repairing the symptoms, such as dry skin and aging, and has a great application prospect.

This invention relates to the field of probiotic screening and application technology, specifically to a Bifidobacterium adolescentis HC2916 that inhibits melanin synthesis, its microbial preparations, and applications. Bifidobacterium adolescentis HC2916 was deposited on May 16, 2023, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 27352. This strain exhibits excellent antioxidant capacity, capable of scavenging various free radicals and inhibiting lipid peroxidation. Furthermore, its fermentation supernatant and lysate significantly downregulate the protein and mRNA expression of MITF, a core factor in melanin production signaling, and inhibit the expression of its downstream key enzymes TYRP1 and TYRP2. This effectively suppresses UVA-induced increases in melanin content in skin keratinocytes, demonstrating promising application prospects in the field of skin whitening.

The invention discloses siRNA (small interfering Ribonucleic Acid) of targeted bone morphogenetic protein 2, modified siRNA and application of the siRNA. According to the invention, siRNA drug design is carried out by taking the BMP2 gene as a target gene to obtain a series of siRNAs, siRNAs capable of effectively silencing the mRNA expression level of the BMP2 gene are screened from the siRNAs, and part of siRNA sequences can even silence the mRNA level of the BMP2 gene to about 25%. The siRNA sequence is further modified, wherein phosphorylation or phosphorylation analogue modification, skeleton modification, sugar ring modification and basic group modification are carried out on the 5'terminal of the sequence, or cholesterol molecule modification is carried out on the end group of the siRNA. The siRNA sequence is further subjected to cholesterol modification to obtain a human-mouse homologous sequence of the targeted BMP2 gene, and the in-vivo silencing activity of the BMP2 target spot is further researched in a mouse experimental model subsequently.

This invention discloses a 5'UTR sequence and its application in improving mRNA translation efficiency. This invention belongs to the field of biotechnology. The 5'UTR sequence designed in this invention has excellent function in promoting mRNA expression. Compared with the commonly used HBA1 gene 5'UTR, the expression level of FLuc mRNA fused with the 5'UTR in this invention can be increased by 2 to 3.5 times.

This invention relates to the field of biomedical technology and discloses a biomarker for diagnosing polycystic ovary syndrome (PCOS) and its application. The diagnostic biomarker is circSPECC1(4), which is formed by reverse splicing and circularization of the fourth exon of the SPECCC1 gene. It has a length of 1580 nt and possesses a closed circular RNA structure. circSPECC1(4) is specifically highly expressed in ovarian granulosa cells of PCOS patients, and there is no significant difference in the mRNA expression level of its parent gene SPECCC1. circSPECC1(4) possesses RNase R nuclease resistance stability and is mainly located in the cytoplasm. Knocking down the expression of circSPECC1(4) can significantly promote apoptosis of ovarian granulosa cells and arrest the ovarian granulosa cell cycle at the G0 / G1 phase. This invention clearly demonstrates that circSPECC1(4) can serve as a specific diagnostic biomarker for PCOS, fully verifying the structural characteristics, expression specificity, and pathological regulatory function of this circular RNA, filling the gap in the existing field of PCOS diagnosis which lacks highly specific and stable molecular diagnostic targets.

The application discloses a pea peptide mixture with calcium binding and osteogenesis promoting effects and application thereof, wherein the pea peptide mixture is derived from protein components in a by-product of pea starch extraction, is obtained through alkaline protease and papain enzymolysis and separation and purification, and is rich in aspartic acid and glutamic acid residues. The pea peptide mixture can effectively bind with calcium ions, the pea peptide mixture can promote calcium ion delivery in osteoblasts, improve alkaline phosphatase activity, and promote osteoblast differentiation, the osteogenesis promoting effect of the pea peptide mixture is related to epidermal growth factor receptor EGFR and downstream PI3K-Akt signal pathway regulation. The pea peptide mixture can improve glucocorticoid-induced zebrafish bone mass reduction, and up-regulate mRNA expression levels of ALP, EGFR, PI3K and Akt and other genes related to osteogenesis. The pea peptide mixture has both functions and nutrition, can be used for preparing products for promoting osteogenesis, improving bone mass, improving bone mass reduction and assisting in improving osteoporosis, and has a wide application prospect in the field of bone health.

The application discloses a use and application based on CDKN1A influence on proliferation and differentiation of goat skeletal muscle, relates to the field of agricultural genetic engineering, and discloses that iRNA-seq and RNA-seq technology reveals mRNA expression maps of the longest dorsal muscle of 5-month-old Hainan black goats and 24-month-old Hainan black goats in two development stages, and CDKN1A with differential expression is screened out; the CDKN1A gene is used for negatively regulating proliferation of goat myoblasts; and the application finds that CDKN1A has a regulation effect on proliferation and differentiation of skeletal muscle cells of Hainan black goats, and can be applied to development and utilization of germplasm resources of the breed and seed selection and breeding.

This invention belongs to the field of biomedicine, specifically relating to siRNA that inhibits MITF gene expression and its applications. The siRNA comprises a sense strand and an antisense strand, which are at least partially anticomplementary to form a double-stranded region. The sense strand or antisense strand consists of a 19-nucleotide blunt-ended complementary nucleotide sequence, or a 19-nucleotide sense strand and a 21-nucleotide antisense strand with overhanging ends. The siRNA of this invention, bound to C16, provides advantages for transdermal delivery, including high penetration, targeting, rapid uptake, and low immunogenicity. By interfering with MITF mRNA expression, melanin production can be reduced at its source.

Provided are a double-stranded RNA (dsRNA) molecule for inhibiting the expression of a target gene via RNAi, and the use thereof, and specifically provided are a modification scheme for the sense strand and antisense strand of a dsRNA.

This invention provides the application of wrinkled papaya polyphenols in the preparation of drugs for treating osteoarthritis. The wrinkled papaya polyphenols are used in the preparation of drugs that reduce the release of pro-inflammatory cytokines and the inflammatory mediator NO in primary chondrocytes, and / or reduce the mRNA expression of inflammation-related enzymes, and / or inhibit the phosphorylation of proteins related to the NF-κB signaling pathway. To test and clarify the anti-inflammatory effect of wrinkled papaya polyphenols, an ADTC5 primary chondrocyte inflammation model was constructed for observation. The results showed that wrinkled papaya polyphenols significantly inhibited IL-1β-induced inflammation in ADTC5 primary chondrocytes, effectively reduced the secretion of pro-inflammatory cytokines (IL-6 and TNF-α), inhibited the release of the inflammatory mediator NO, downregulated the mRNA expression of inflammatory enzymes (iNOS and Cox-2), and reduced the phosphorylation of IκBα and p65 proteins.

Provided herein are, inter alia, agents (e.g., RNAi agents, dsRNA agents) comprising a sense strand and an antisense strand targeting CIDEB (e.g., hCIDEB); and methods of manufacturing and pharmaceutical compositions comprising the same. Further provided herein are methods of utilizing the agents (e.g., RNAi agents, dsRNA agents) including, e.g., methods of inhibiting or decreasing CIDEB expression (e.g., mRNA expression), methods of treating CIDEB associated diseases, and methods of treating liver diseases (e.g., MASH).

Provided is a single-stranded oligonucleotide which can inhibit AGT mRNA expression via the RNAi mechanism and has a length of 16-30 nucleotides, wherein each nucleotide is independently a modified or unmodified nucleotide, at least one nucleotide is a nucleotide X, and at least one nucleotide is a fluoro-modified nucleotide; furthermore, along the 5'-end-to-3'-end direction, the 13th nucleotide is a nucleotide modified with a substituted alkoxy group, the 14th nucleotide is a nucleotide X, and each of the 15th nucleotide and all the nucleotides thereafter is independently a modified nucleotide. Further provided are a double-stranded oligonucleotide containing the single-stranded oligonucleotide as an antisense strand, an oligonucleotide conjugate, and a pharmaceutical composition.

This invention discloses the application of the USP28 gene in the proliferation of porcine muscle stem cells, belonging to the field of animal genetic engineering. Resequencing data shows that this gene is selected in pig breeds with high meat production traits. Functional verification indicates that knocking down this gene in primary porcine muscle stem cells significantly reduces the mRNA expression level of the proliferation marker gene and significantly decreases the number of EdU-labeled proliferative positive cells. This invention clarifies the proliferation-promoting function of the USP28 gene, which can be used as a molecular marker or target gene for pork quality improvement and new breed breeding, providing an effective technical means to solve the problems of insufficient pork yield and genetic improvement of quality traits.

This invention provides a 5'UTR for enhancing mRNA expression and its applications. Firstly, this invention provides a nucleic acid molecule selected from one or more nucleic acid molecules shown in any one of SEQ ID NO:3, 5, 8-12, and 14. This invention also provides nucleic acid constructs, recombinant vectors, host cells, mRNA, cells transfected with mRNA, and related applications prepared using any one of the sequences in SEQ ID NO:3, 5, 8-12, and 14 as a 5'UTR. The nucleic acid molecule of this invention, as a 5'UTR, can improve mRNA expression levels and shows excellent promise for application in nucleic acid therapeutics or mRNA vaccines.

The application discloses application of a Portulaca oleracea extracellular vesicle in resisting acne and regulating acne microecological flora. The Portulaca oleracea extracellular vesicle PDEVs provided by the application can significantly inhibit growth of Propionibacterium acnes, and has obvious bactericidal effect under a lower MIC condition, has less influence on skin beneficial bacteria, is helpful to maintaining or regulating skin microecological balance, and has the advantage of selectively regulating skin flora. Meanwhile, the PDEVs can significantly reduce mRNA expression levels of inflammatory factors IL-6, IL-8, IL-1beta and TNF-alpha of HaCaT cells under stimulation of inactivated Propionibacterium acnes and intracellular reactive oxygen species ROS levels, thereby reducing inflammatory reaction and oxidative stress reaction; the PDEVs have a synergistic effect in regulating skin microecology, inhibiting inflammatory reaction and relieving oxidative stress, have good biocompatibility and safety, and provide more choices for developing natural source active ingredients for preventing or improving acne.

The present invention is characterized by a multinucleotide construct comprising a sequence targeting α-synuclein mRNA. Constructs comprising the sequence targeting α-synuclein mRNA and / or its coding sequence can be used, for example, to inhibit α-synuclein mRNA expression and / or to treat synucleinosis diseases or conditions.

This invention discloses a 5'UTR sequence and its application in improving mRNA translation efficiency. This invention belongs to the field of biotechnology. The 5'UTR sequence designed in this invention has excellent function in promoting mRNA expression. Compared with the commonly used HBA1 gene 5'UTR, the expression level of FLuc mRNA fused with the 5'UTR in this invention can be increased by 2 to 3.5 times.

The application discloses a lactobacillus rhamnosus capable of improving oxidative damage to relieve vaginitis, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus has the effect of repairing oxidative damage related symptoms caused by vaginitis, and further improves intestinal health problems caused by vaginitis, specifically embodied in: reducing cell Keap1 mRNA expression, increasing cell supernatant Nrf2 content; improving mouse vaginal oxidative stress: activating the Keap1 / Nrf2 pathway, increasing the Nrf2 level of vaginal tissue; enhancing the antioxidant capacity of the mouse intestinal tract: reducing the Keap1 mRNA level of colon tissue; improving the pathological characteristics of the mouse vagina and reducing the pathogenic bacterial load. Therefore, the lactobacillus rhamnosus CCFM1315 has great application prospect in products for improving and repairing the vaginal oxidative damage problems caused by vaginitis.

Provided herein are, inter alia, agents (e.g., RNAi agents, dsRNA agents) comprising a sense strand and an antisense strand targeting ZBTB7A (e.g., hZBTB7A); and methods of manufacturing and pharmaceutical compositions comprising the same. Further provided herein are methods of utilizing the agents (e.g., RNAi agents, dsRNA agents) including, e.g., methods of inhibiting or decreasing ZBTB7A expression (e.g., mRNA expression), methods of treating ZBTB7A associated diseases.

Provided herein are, inter alia, agents (e.g., dsRNA agents comprising a sense strand and an antisense strand; RNAi agents, ssRNAs, ASOs) comprising a sense strand and an antisense strand targeting BCL11A (e.g., hBCL11A); and methods of manufacturing and pharmaceutical compositions comprising the same. Further provided herein are methods of utilizing the agents (e.g., dsRNA agents comprising a sense strand and an antisense strand; RNAi agents, ssRNAs, ASOs) including, e.g., methods of inhibiting or decreasing BCL11A expression (e.g., mRNA expression), methods of treating BCL11A associated diseases.

This invention discloses a heat-inactivated Lactobacillus rhamnosus. rhamnosus This invention relates to strain CQFP202442 and its application in alleviating exercise-induced fatigue, belonging to the field of microbial technology. The preservation number of this heat-inactivated strain is CGMCC No. 29612. This invention demonstrates that this heat-inactivated strain can significantly prolong the time to exhaustion during running in mice and reduce the degree of muscle damage; it can increase the levels of T-AOC, CAT, GSH, and GLU in mouse serum, as well as the relative mRNA expression levels of SOD1, SOD2, and CAT in mouse muscle tissue; simultaneously, it can upregulate the relative expression levels of related mRNAs in muscle tissue; and downregulate the levels of LDH, BUN, and CRE in mouse serum. The heat-inactivated strain of this invention can effectively alleviate exercise-induced fatigue through a dual mechanism of regulating oxidative stress and myofibrillary protection, exhibiting high safety and good stability.

The application discloses application of compound C-08 in improving ulcerative colitis and intestinal barrier function, and belongs to the technical field of medicines.The application screens the compound C-08, and verifies the improvement effect of the compound C-08 on ulcerative colitis, including the effect of improving ulcerative colitis and repairing intestinal barrier function; the compound C-08 can significantly inhibit the weight loss of a DSS-induced mouse, obviously down-regulate the expression of a colon proinflammatory factor IL1-beta, restore the colon length and reduce a disease activity index, and has the effect of improving ulcerative colitis, thereby providing a new target for the treatment of ulcerative colitis; the compound C-08 can promote the mRNA expression amount of intestinal tight junction to increase and tend to be normal, and has the effect of improving intestinal barrier dysfunction.

This invention provides a high-throughput and efficient method for screening multiple target genes that can regulate mRNA expression levels in cells by co-transfecting or sequentially transfecting mRNA with a gene silencing library targeting genes in cells using lipid nanoparticles. Several target genes that can regulate mRNA protein expression levels through the action of siRNA have been discovered. By manipulating these genes that regulate mRNA expression levels, the translational capacity of mRNA in mRNA vaccine and drug development can be improved, mRNA protein expression efficiency can be increased, and immunogenicity and toxicity can be reduced.

Methods of determining methylation of DNA are provided that include filtering a biological sample comprising a nucleic acid with a first matrix material to purify the DNA; eluting and denaturing the DNA to produce eluted denatured DNA; heating the DNA in the presence of bisulfite ions to produce deaminated nucleic acid; optionally contacting said deaminated nucleic acid with a second matrix material; desulphonating and eluting the bound deaminated nucleic acid; and performing methylation specific PCR, nucleic acid sequencing, and / or high resolution melting analysis (HRM) on said bisulfite-converted nucleic acid to determine the methylation of said nucleic acid, wherein multiple steps may be performed in a single reaction cartridge.

The present application relates to the technical field of biological medicine, and particularly relates to siRNA targeting CD177 and application thereof in preparation of a medicine for treating NLRP3 gene mutation related diseases, the siRNA targeting CD177 can significantly reduce peripheral blood CD177 expression and significantly reduce CD177 mRNA expression in skin, liver and spleen; can significantly reduce the number of peripheral blood neutrophils and IL-6 and IL-1 beta positive cell proportion; can significantly reduce IL-6, IL-1 beta and TNF-alpha expression in tissues and serum. The siRNA targeting CD177 can effectively relieve NLRP3 mutation related multi-organ inflammation, and the effect is better than that of traditional anti-inflammatory treatment (such as IL-6 blocking or IL-1 beta neutralizing antibody), and is a very promising treatment strategy.